X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Approvals - 08/Aug 22:08

FDA Approves Lymphir (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

CRANFORD, N.J., Aug. 8, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S. Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl), a novel...

Articles similaires

Sorry! Image not available at this time

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

zacks.com - 14:47

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...

Sorry! Image not available at this time

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

haei.org - 03/Sep 17:29

KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...

Sorry! Image not available at this time

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Sorry! Image not available at this time

WellSync and Marius Pharmaceuticals Collaborate to Offer FDA-approved Oral Testosterone Replacement Therapy, Expanding Virtual Care for Men's Health

healthtechzone.com - 09/Sep 11:00

Sorry! Image not available at this time

New Pooled Analysis Published in The Lancet Demonstrated Reduced Risk of Combined CV Death or Worsening Heart Failure with Semaglutide

drugs.com - 30/Aug 03:09

PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...

Sorry! Image not available at this time

New Pooled Analysis Published in The Lancet Demonstrated Reduced Risk of Combined CV Death or Worsening Heart Failure with Semaglutide

drugs.com - 30/Aug 03:09

PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...

Sorry! Image not available at this time

Immune cell ‘atlas’ will help kids fight life-threatening diseases

oncologynews.com.au - 13:59

Researchers at The University of Queensland are developing a comprehensive paediatric immune cell ‘atlas’ to aid in the diagnosis and treatment of...

Sorry! Image not available at this time

Emergent BioSolutions’ ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication

drugs.com - 29/Aug 04:08

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Emergent BioSolutions’ ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication

drugs.com - 29/Aug 04:08

GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

Bora Pharma to invest into Tanvex Biopharma to provide global biomanufacturing services

pharmabiz.com - 29/Aug 00:00

Bora Pharmaceuticals Co., Ltd. (Bora), a leading global pharmaceutical manufacturer, announced that its board of directors has approved a strategic...

Les derniers communiqués